A comparative study of treatment outcome in younger and older patients with locally advanced oral cavity and oropharyngeal cancers treated by chemoradiation.
Concurrent chemoradiation
disease-free survival
mucositis
oropharyngeal cancer
xerostomia
Journal
South Asian journal of cancer
ISSN: 2278-330X
Titre abrégé: South Asian J Cancer
Pays: India
ID NLM: 101618774
Informations de publication
Date de publication:
Historique:
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
16
2
2019
Statut:
ppublish
Résumé
Evidence suggests that older patients with oral cavity and oropharyngeal cancers may behave differently from their younger peers. The aim of this study is to determine if there is difference in responses, survival, and toxicities between young patients (≤40 years of age) with oral cavity and oropharyngeal cancers and older patients (>40 years of age) treated with concurrent chemoradiation. Sixty-one patients with unresectable, locally advanced oral cavity and oropharyngeal cancers received concomitant chemoradiation to a dose of 70 Gray in 35 fractions over 7 weeks with concomitant weekly cisplatin (40 mg/m The overall response rate (complete responders + partial responders) evaluated using response evaluation criteria in solid tumors criteria version 1.1 was equivalent in both groups (80.76% in Arm-A and 74.28% in Arm-B; Older patients with locally advanced oral cavity and oropharyngeal cancers have similar response rates and survival as compared to their younger counterparts but may experience higher treatment-related toxicities.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence suggests that older patients with oral cavity and oropharyngeal cancers may behave differently from their younger peers.
AIM
OBJECTIVE
The aim of this study is to determine if there is difference in responses, survival, and toxicities between young patients (≤40 years of age) with oral cavity and oropharyngeal cancers and older patients (>40 years of age) treated with concurrent chemoradiation.
MATERIALS AND METHODS
METHODS
Sixty-one patients with unresectable, locally advanced oral cavity and oropharyngeal cancers received concomitant chemoradiation to a dose of 70 Gray in 35 fractions over 7 weeks with concomitant weekly cisplatin (40 mg/m
RESULTS
RESULTS
The overall response rate (complete responders + partial responders) evaluated using response evaluation criteria in solid tumors criteria version 1.1 was equivalent in both groups (80.76% in Arm-A and 74.28% in Arm-B;
CONCLUSIONS
CONCLUSIONS
Older patients with locally advanced oral cavity and oropharyngeal cancers have similar response rates and survival as compared to their younger counterparts but may experience higher treatment-related toxicities.
Identifiants
pubmed: 30766854
doi: 10.4103/sajc.sajc_7_18
pii: SAJC-8-47
pmc: PMC6348780
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47-51Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Cancer. 2000 Feb 1;88(3):648-52
pubmed: 10649260
Laryngoscope. 1999 Feb;109(2 Pt 1):249-58
pubmed: 10890775
Head Neck. 2002 Feb;24(2):165-80
pubmed: 11891947
Oral Surg Oral Med Oral Pathol. 1992 Sep;74(3):404-8
pubmed: 1408010
Clin Otolaryngol Allied Sci. 1992 Feb;17(1):18-23
pubmed: 1555311
J Oral Pathol Med. 2005 Mar;34(3):129-33
pubmed: 15689225
Head Neck. 2005 Apr;27(4):269-73
pubmed: 15700292
Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):108-12
pubmed: 16629526
J Oncol. 2011;2011:525976
pubmed: 21547265
Oncologist. 2013;18(5):568-78
pubmed: 23635557
J Laryngol Otol. 1990 Jul;104(7):544-8
pubmed: 2384710
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Ann N Y Acad Sci. 1988;521:99-109
pubmed: 3377369
Br J Plast Surg. 1987 May;40(3):270-3
pubmed: 3594055
Cancer. 1985 Jan 15;55(2):441-4
pubmed: 3965099
J Surg Oncol. 1982 Feb;19(2):65-8
pubmed: 7057649
Otolaryngol Head Neck Surg. 1995 Sep;113(3):197-203
pubmed: 7675478
Eur J Cancer. 1996 Nov;32A(12):2075-81
pubmed: 9014748